Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE). ORBIT-4 is the second of the two Phase III pivotal

The 100000 Genomes Project

If you have unexplained Bronchiectasis then you may qualify for the Genomes Project to identify what has caused your bronchiectasis.